Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China · Delayed Price · Currency is CNY 26.08
-0.42 (-1.58%)
Feb 13, 2026, 3:12 PM CST
SHE:300204 Revenue
Staidson (Beijing) BioPharmaceuticals had revenue of 54.94M CNY in the quarter ending September 30, 2025, a decrease of -30.10%. This brings the company's revenue in the last twelve months to 244.37M, down -30.32% year-over-year. In the year 2024, Staidson (Beijing) BioPharmaceuticals had annual revenue of 324.82M, down -10.81%.
Revenue (ttm)
244.37M
Revenue Growth
-30.32%
P/S Ratio
50.99
Revenue / Employee
496.68K
Employees
484
Market Cap
12.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 324.82M | -39.36M | -10.81% |
| Dec 31, 2023 | 364.18M | -184.81M | -33.66% |
| Jan 1, 2023 | 548.99M | -35.30M | -6.04% |
| Dec 31, 2021 | 584.29M | 159.08M | 37.41% |
| Dec 31, 2020 | 425.21M | -236.28M | -35.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition